Edition:
United Kingdom

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

7.95USD
5:35pm GMT
Change (% chg)

$-0.40 (-4.79%)
Prev Close
$8.35
Open
$8.15
Day's High
$8.45
Day's Low
$7.80
Volume
28,126
Avg. Vol
20,159
52-wk High
$13.30
52-wk Low
$4.10

Latest Key Developments (Source: Significant Developments)

Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Trillium Therapeutics Inc ::MATRIX CAPITAL MANAGEMENT COMPANY LP REPORTS A 16.5 PCT PASSIVE STAKE IN TRILLIUM THERAPEUTICS INC <<>> AS OF NOV 30 - SEC FILING.  Full Article

Trillium announces private placement to fund development of cancer drugs
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Trillium Therapeutics Inc -:Trillium announces private placement.Trillium Therapeutics - ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares​.Trillium Therapeutics - ‍net proceeds from private placement will be used to continue development of TTI-621 in hematologic cancers and solid tumors​.Trillium Therapeutics Inc - ‍subscription agreements for offering at a price of U.S.$8.50 per share.  Full Article

Trillium Therapeutics reports Q3 results
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Trillium Therapeutics Inc :Trillium Therapeutics reports third quarter 2017 financial and operating results.Trillium Therapeutics Inc - ‍Cash and marketable securities of $64.3 million at September 30, 2017​.  Full Article

Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial
Tuesday, 31 Jan 2017 

Trillium Therapeutics Inc :Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial.  Full Article

Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial
Tuesday, 31 Jan 2017 

Trillium Therapeutics Inc :Trillium Therapeutics doses first patient with TTI-621 in phase 1 solid tumor trial.  Full Article

Trillium Therapeutics Inc acquires Privately-Held Fluorinov Pharma Inc
Wednesday, 27 Jan 2016 

Trillium Therapeutics Inc:Announced that it has acquired all of the outstanding shares of Fluorinov Pharma Inc., a privately-held oncology company.Trillium has agreed to acquire all of the outstanding shares of Fluorinov for an upfront payment of C$10 million in cash, plus up to C$35 million of additional future payments that are contingent.  Full Article

BRIEF-Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics

* MATRIX CAPITAL MANAGEMENT COMPANY LP REPORTS A 16.5 PCT PASSIVE STAKE IN TRILLIUM THERAPEUTICS INC AS OF NOV 30 - SEC FILING Source text: (http://bit.ly/2yOHuTW) Further company coverage: